About KaloCyte
KaloCyte is a company based in St. Louis (United States) founded in 2016 by Dipanjan Pan, Philip Spinella, and Allan Doctor. KaloCyte has raised $1.1 million across 6 funding rounds from investors including HHS, NYBC Ventures and Maryland Momentum Fund. KaloCyte offers products and services including ErythroMer. KaloCyte operates in a competitive market with competitors including Satellite Bio, CorNeat Vision, Stratatech Corp, Morphocell Technologies and Haimai Medical, among others.
- Headquarter St. Louis, United States
- Founders Dipanjan Pan, Philip Spinella, Allan Doctor
- SectorsHealthcare
- Website kalocyte.com
- Social LinkedIn
- Legal Name Kalocyte, Inc.
- Total Equity Funding$1.1M (USD)
in 6 rounds
- Latest Funding Round$2.46M (USD), Grant
Apr 2024
- InvestorsHHS
& 2 more
Products & Services of KaloCyte
KaloCyte offers a comprehensive portfolio of products and services, including ErythroMer.
Dried substitute for red blood cells in trauma and emergencies.
Funding Insights of KaloCyte
KaloCyte has successfully raised a total of $1.1M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.46 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.1M
- Total Rounds 6
- Last Round Grant — $2.46M
- First Round $4.57M
(May 2017)
- Investors Count 3
All 6 funding rounds of KaloCyte with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $2.46M | Grant | – | – | |
| Jul 2022 | – | Seed | – | – | |
| Jun 2020 | $300,000 | Seed | – | Maryland Momentum Fund | – |
| May 2020 | $373,216 | Grant | – | – | |
| Apr 2018 | $800,000 | Seed | – | – | – |
| May 2017 | $4.57M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in KaloCyte
KaloCyte has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NYBC Ventures and Maryland Momentum Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | nybcventures.com | - | |
Investment funding is provided for University System of Maryland ventures. | – | momentum.usmd.edu | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for KaloCyte
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of KaloCyte
7 people are tracked at KaloCyte (5 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Dipanjan Pan | Co-Founder | Leadership |
Philip Spinella | Co-Founder | Leadership |
Allan Doctor | Co-Founder | Leadership |
Elaine Haynes | President and CEO, Board Director | Leadership |
George Allen Hides | Vice President, Regulatory Affairs and Operations | Leadership |
Stephen R. | Manager, Administration & Human Resources | Team |
Tom Krenning | Project Manager, Agile Coach, and Regulatory Writing Consultant | Team |
Complete people profiles for KaloCyte
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of KaloCyte
3 dated milestones of KaloCyte across 8 years, from founding to its latest funding, stage changes and deals.
- Founded KaloCyte is founded.
- Funding First funding round of $4.6M.
- Funding Latest funding round, Grant, of $2.5M.
Competitors of KaloCyte
KaloCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Satellite Bio, CorNeat Vision, Stratatech Corp, Morphocell Technologies and Haimai Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| satellite.bio | 2019 | Cambridge, United States | $110M | 21 | Proprietary implantable satellite organs are developed for cell therapy. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| stratatechcorp.com | 2000 | United States | $3.68M | 47 | Cell-based skin substitutes are developed for therapeutic and research uses. | |
| morphocell.com | 2018 | Montreal, Canada | – | – | Engineered liver tissues are developed for liver disease treatments. | |
| humatrix-medical.com | 2021 | Suzhou, China | – | – | Tissue engineering technologies for cardiovascular regenerative surgeries are developed. | |
| videregen.com | 2012 | Liverpool, United Kingdom | $2.59M | 8 | Tissue repair is advanced through thymus stem cell science by Videregen. | |
| golivertx.com | 2017 | Nantes, France | – | – | Develops stem cell-based therapies to repair liver without transplantation. | |
| juntenbio.co.jp | 2018 | Chiyoda, Japan | – | – | Regenerative medicine products are developed for immune tolerance induction. |
Detailed competitors of KaloCyte
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of KaloCyte
The website of KaloCyte (kalocyte.com) receives about 1.8K visits a month.
- Monthly visits1.8K
▲ 13.9% vs previous month
Latest news on Kalocyte
Complete news archive for KaloCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to KaloCyte
10 companies that operate in the same segment as KaloCyte (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 442 M | – | 66 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 14 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about KaloCyte
KaloCyte was founded in 2016 and raised its 1st funding round 1 year after it was founded.
KaloCyte is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
KaloCyte is a funded company, having raised a total of $1.1M across 6 funding rounds to date. The company's 1st funding round was a Grant of $4.57M, raised on May 2017.
KaloCyte was founded in 2016 in St. Louis, United States, within the biotechnology sector. A nanotechnology platform is utilized to create ErythroMer, an immuno-silent nanoparticle designed to mimic red blood cell surfaces and facilitate oxygen binding and gas exchange. The technology is directed toward trauma care in low-resource environments, such as battlefields and remote areas, to address blood loss mortality. Operations focus on advancing this substitute for clinical applications.
KaloCyte's top competitors include Satellite Bio, Stratatech Corp and Morphocell Technologies.
KaloCyte offers ErythroMer.
KaloCyte has 3 investors. Key investors include HHS, NYBC Ventures, and Maryland Momentum Fund.
KaloCyte operates through Kalocyte, Inc..